/PRNewswire/ I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up in the field of GMP cell manufacturing CDMO, announced that the company,.
/PRNewswire/ I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP.
/PRNewswire/ I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up, announced that its cell manufacturing facility is now listed on the FDA.
/PRNewswire/ I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-winning technology "induced pluripotent stem cells.
Share this article
Share this article
I Peace s GMP-grade iPSCs are key to manufacture Avery Therapeutics MyCardia™, a proprietary tissue-engineered heart graft developed to treat heart failure
TUCSON, Ariz. and PALO ALTO, Calif., Dec. 16, 2020 /PRNewswire/ Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs), announced a service agreement to advance cell therapy for heart failure. Under the agreement, I Peace will generate and supply GMP-grade induced pluripotent stem cells (iPSCs) and related services to Avery Therapeutics. Avery Therapeutics will use the iPSCs to derive cells used in the manufacturing of MyCardia